Christin A. Knowlton, MD, MA
Associate Professor of Therapeutic RadiologyCards
Appointments
Additional Titles
Medical Director, Smilow Cancer Hospital Care Center-Hamden, Therapeutic Radiology
Contact Info
Therapeutic Radiology
PO Box 208040
New Haven, CT 06520-8040
United States
Appointments
Additional Titles
Medical Director, Smilow Cancer Hospital Care Center-Hamden, Therapeutic Radiology
Contact Info
Therapeutic Radiology
PO Box 208040
New Haven, CT 06520-8040
United States
Appointments
Additional Titles
Medical Director, Smilow Cancer Hospital Care Center-Hamden, Therapeutic Radiology
Contact Info
Therapeutic Radiology
PO Box 208040
New Haven, CT 06520-8040
United States
About
Titles
Associate Professor of Therapeutic Radiology
Medical Director, Smilow Cancer Hospital Care Center-Hamden, Therapeutic RadiologyBiography
Dr. Christin Knowlton provides expertise in breast cancer radiation oncology and high-quality patient centered care in Hamden. She specializes in radiation therapy for breast cancer, lung cancer, bone metastases, and thymoma and says she was drawn to her field because it provides the opportunity to treat cancer often with tangible results. Dr. Knowlton says the best part of her job is meeting patients and answering questions about their disease process and treatment options. She received her medical degree from SUNY at Stonybrook. In 2019 she received the Smilow Luminary Award of Excellence in Patient Care.
Appointments
Therapeutic Radiology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Residency
- Hahnemann University Hospital/Drexel University College of Medicine (2011)
- MD
- SUNY at Stonybrook (2006)
- MA
- New York University, Education (1998)
- BA
- Oberlin College (1994)
Research
Overview
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Nadine Housri, MD
Meena S. Moran, MD
Henry S. Park, MD, MPH
Lynn D. Wilson, MD, MPH, FASTRO
Suzanne B. Evans, MD, MPH, FASTRO
Thomas Hayman, MD, PhD
Breast Neoplasms
Publications
2024
Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchAltmetricConceptsLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchConceptsHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchConceptsHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsBilateral Breast Cancer With Contralateral Axillary Metastasis Warrants Aggressive Treatment: Let's Go for It!
Mokhtech M, Knowlton C. Bilateral Breast Cancer With Contralateral Axillary Metastasis Warrants Aggressive Treatment: Let's Go for It! International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 527-528. PMID: 37739602, DOI: 10.1016/j.ijrobp.2023.03.039.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsInterim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
Peters G, Cheng W, Boateng K, Knowlton C, Campbell A, Hayman T, Park H. Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e46-e47. DOI: 10.1016/j.ijrobp.2023.06.750.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyPhase Ib/II trialCentral lung tumorsCancer-specific survivalProgression-free survivalLocal recurrenceLung tumorsInterim analysisII trialAdverse eventsOverall survivalDistant controlLocal controlGrade 2 adverse eventsUltra-central lung tumorsRisk dose constraintsRate of gradeSecondary lung tumorsCo-primary endpointsHigh toxicity ratesBiologically equivalent doseBody radiation therapyMATERIAL/METHODSRTOG 0236RTOG 0813Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysisSurvival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
Verma N, Ninia J, Hayman T, Housri N, Peters G, Knowlton C, Campbell A, Park H. Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e68-e69. DOI: 10.1016/j.ijrobp.2023.06.797.Peer-Reviewed Original ResearchConceptsLocal recurrence-free survivalProgression-free survivalES-SCLC patientsES-SCLCOligometastatic diseaseOligometastatic patientsImproved OSLung involvementExtensive-stage small-cell lung cancerMultivariable Cox proportional hazards regressionMultivariable Cox regression analysisCox proportional hazards regressionSmall cell lung cancerBilateral lung involvementConsolidative thoracic radiotherapyLimited metastatic burdenMetastasis-directed radiotherapyPlatinum-doublet chemotherapyCox regression analysisMetastasis-free survivalRecurrence-free survivalTime of diagnosisProportional hazards regressionCell lung cancerLog-rank test
2022
Risk Assessment in the Molecular Era
Knowlton CA, Jimenez RB, Moran MS. Risk Assessment in the Molecular Era. Seminars In Radiation Oncology 2022, 32: 189-197. PMID: 35688517, DOI: 10.1016/j.semradonc.2022.01.005.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBreast-conserving surgeryClinical-pathologic featuresHormone receptor-positive diseaseLow-risk DCIS patientsLow-risk DCISAdjuvant endocrine therapyLocal control rateMajority of patientsSpecific survival outcomesPersonalized risk assessmentMolecular assaysBreast recurrenceDCIS patientsDCIS ScoreRT recommendationsDefinitive surgeryEndocrine therapyPostoperative radiotherapyPositive diseaseDuctal carcinomaSurvival outcomesControl rateInvasive cancerTreatment paradigmBreast cancer
2021
Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated
Peters GW, Gao SJ, Knowlton C, Zhang A, Evans SB, Higgins S, Wilson LD, Saltmarsh N, Picone M, Moran MS. Benefit of Deep Inspiratory Breath Hold for Right Breast Cancer When Regional Lymph Nodes Are Irradiated. Practical Radiation Oncology 2021, 12: e7-e12. PMID: 34508890, DOI: 10.1016/j.prro.2021.08.010.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRight-sided breast cancerRegional nodal irradiationLiver VBreast cancerLung VDIBH plansLiver parametersLung doseComprehensive regional nodal irradiationLeft-sided breast cancerRight breast cancerWilcoxon signed-rank testingRegional lymph nodesTotal liver volumeIpsilateral lung VLiver DHeart VNodal irradiationRBC patientsHeart doseLymph nodesInspiratory breathLiver volumeLarge cohortTreatment plan
Clinical Trials
Current Trials
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
HIC ID2000030031RoleSub InvestigatorPrimary Completion Date05/01/2028Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RoleSub InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RoleSub InvestigatorPrimary Completion Date01/31/2030Recruiting Participants
Academic Achievements and Community Involvement
honor Smilow Luminary Award of Excellence: Patient Care
Other AwardSmilow Cancer HospitalDetails10/18/2019United Stateshonor National Comprehensive Cancer Network (NCCN) Fellows Recognition Program
National AwardDetailsUnited States
Clinical Care
Overview
Christin Knowlton, MD, is a therapeutic radiologist and is medical director of the Smilow Cancer Care Center in Hamden. Dr. Knowlton specializes in radiation therapy for breast cancer, lung cancer, bone metastases, and thymoma.
Dr. Knowlton says she was drawn to her field because it provides the opportunity to treat cancer “often with tangible results.”
“Radiation therapy is very successful at killing cancer cells and also helping with symptoms such as pain or bleeding from tumors,” she says. “In addition, some courses of radiation therapy span several days to weeks, which allows the physician the opportunity to really get to know the patients and their families.”
In fact, Dr. Knowlton says the best part of her job is meeting patients and answering questions about their disease process and treatment options.
“I also enjoy working closely with the members of the department of radiation oncology, including nursing, physics, dosimetry (treatment planning), and therapy to provide high-quality, patient-centered care,” she adds. “We work as a team to provide the best possible care for each patient.”
Clinical Specialties
Fact Sheets
Radiation Therapy
Learn More on Yale MedicineBrachytherapy
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- December 15, 2021
Video: Meet Dr. Christin Knowlton
- December 06, 2021
Smilow Breast Cancer Multispecialty Care
- October 21, 2021
Understanding Breast Cancer: Treatment Advances and Patient Care
- October 15, 2021
Breast Cancer Awareness Q&A with Therapeutic Radiologist, Christin Knowlton, MD
Related Links
Get In Touch
Contacts
Therapeutic Radiology
PO Box 208040
New Haven, CT 06520-8040
United States